Marie E. Fallon - Mar 11, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Accounting Officer
Signature: /s/ Karen Tepichin, Attorney-in-fact
Stock symbol: DNA
Transactions as of: Mar 11, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/14/2022, 09:32 PM
Previous filing: Jan 26, 2022
Next filing: Oct 7, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Class B Common Stock	Award	$0	+150K	+151.68%	$0.00	249K	Mar 11, 2022	Class A Common Stock	150K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F2	Represents an award of restricted stock units covering Class B Common Stock, which vests in 48 equal monthly installments following the vesting commencement date of March 1, 2022.
F3	Includes 40,000 restricted stock units covering Class B Common Stock that were previously reported as Restricted Stock Units on the Form 4 filed by the reporting person on January 26, 2022. The reporting person intends to report such restricted stock units on a consolidated basis with her holdings of the underlying Class B Common Stock in future reports.

Remarks:

Chief Accounting Officer